Primary candidates for GLP-1 therapy include: Patients with type 2 diabetes and inadequate glycemic control despite metformin therapy Individuals with type 2 diabetes and established atherosclerotic cardiovascular disease Patients with type 2 diabetes and multiple cardiovascular risk factors (hypertension, dyslipidemia, obesity) Adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with weight-related comorbidities Patients with metabolic syndrome who have not achieved adequate risk factor control with lifestyle modification For patients with dyslipidemia, GLP-1 agents may be particularly valuable when combined with statin therapy in those who have not reached LDL-C goals or who have persistent hypertriglyceridemia despite statin treatment
Contact your healthcare provider if you have any questions or concerns about your medication
Despite similar pancreas weight compared with their Sst-cre littermates, the Sst Cre R26 DTA mice exhibited dramatic increases in the levels of both plasma and pancreatic insulin, by approximately twofold higher than those of Sst-cre mice (Figs
A liquid facelift is a minimally invasive injectable procedure that is generally considered to be very comfortable by our patients
CTLA-4 is a modulator of Tregs (80) and these cells act as gatekeepers for the prevention of autoimmunity
Understanding the difference between them is the key to understanding why the combination is studied at all